Johnson & Johnson has presented data showing its COVID-19 vaccine candidate provides protection for animals with a single dose, and has now progressed into Phase I/II human studies.
The data, published in Nature show its investigational adenovirus serotype 26 (Ad26) vector-based vaccine elicited a robust immune response as...






